Oneness Biotech Co., Ltd.

This study tests a drug called FB825 in adults with moderate-to-severe atopic dermatitis (eczema). Participants receive five injections over 12 weeks, either FB825 or a placebo, to see if it improves skin symptoms like redness and itching. The goal is to find a new treatment opti…

This study tests whether a new drug, FB825, can help adults with moderate-to-severe allergic asthma. About 100 participants will receive either FB825 or a placebo. The main goal is to see if FB825 reduces asthma attacks over 24 weeks.

This study tests a new medicine called FB704A in adults with severe asthma. The goal is to see if it is safe and can help control asthma symptoms. About 20 people will receive either the drug or a placebo over 8 weeks, with follow-up for 12 more weeks.

This early-stage study is testing a new drug, SNS851, in 52 healthy adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo by injection. The goal is to check for side effects, not to treat any disease.